Cargando…

Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties

Antibody-based therapeutics represent an important class of biopharmaceuticals in cancer immunotherapy. CD3 bispecific T-cell engagers activate cytotoxic T-cells and have shown remarkable clinical outcomes against several hematological malignancies. The absence of a costimulatory signal through CD28...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elsayed, Abdullah, Pellegrino, Christian, Plüss, Louis, Peissert, Frederik, Benz, Ramon, Ulrich, Franziska, Thorhallsdottir, Gudrun, Plaza, Sheila Dakhel, Villa, Alessandra, Mock, Jacqueline, Puca, Emanuele, De Luca, Roberto, Manz, Markus G., Halin, Cornelia, Neri, Dario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251795/ https://www.ncbi.nlm.nih.gov/pubmed/37288872 http://dx.doi.org/10.1080/19420862.2023.2220839

Ejemplares similares

Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen
por: Plüss, Louis, et al.
Publicado: (2023)

CD28 Superagonist Shock and Blockage of Motogenic T Cell Cascade
por: Sundqvist, Karl-Gösta
Publicado: (2021)

Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
por: Waibler, Zoe, et al.
Publicado: (2008)

Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody Superagonists
por: Lühder, Fred, et al.
Publicado: (2003)

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease
por: Dakhel, Sheila, et al.
Publicado: (2021)

Rapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice
por: Gogishvili, Tea, et al.
Publicado: (2009)

CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program
por: Thaventhiran, Thilipan, et al.
Publicado: (2019)

Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis
por: Beyersdorf, Niklas, et al.
Publicado: (2005)

Self-Recognition Sensitizes Mouse and Human Regulatory T Cells to Low-Dose CD28 Superagonist Stimulation
por: Langenhorst, Daniela, et al.
Publicado: (2018)

Are there superagonists for calcium-activated potassium channels?
por: Brown, Brandon M., et al.
Publicado: (2017)

Revisiting CD28 Superagonist TGN1412 as Potential Therapeutic for Pediatric B Cell Leukemia: A Review
por: Brown, Katelyn E.
Publicado: (2018)

Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody
por: Nadal, Lisa, et al.
Publicado: (2022)

Inhibition of ZAP-70 Kinase Activity via an Analog-sensitive Allele Blocks T Cell Receptor and CD28 Superagonist Signaling
por: Levin, Susan E., et al.
Publicado: (2008)

Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist
por: Thaventhiran, Thilipan, et al.
Publicado: (2014)

Combinations of anti-GITR antibody and CD28 superagonist induce permanent allograft acceptance by generating type 1 regulatory T cells
por: Que, Weitao, et al.
Publicado: (2022)

Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson’s disease mice
por: Badr, Mohammad, et al.
Publicado: (2022)

CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke
por: Schuhmann, Michael K, et al.
Publicado: (2015)

Superagonistic CD28 protects against renal ischemia injury induced fibrosis through a regulatory T-cell expansion dependent mechanism
por: Liang, Yiran, et al.
Publicado: (2019)

Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor
por: Thirunarayanan, Nanthakumar, et al.
Publicado: (2012)

New Roles for Vitamin D Superagonists: From COVID to Cancer
por: Easty, David J., et al.
Publicado: (2021)

Adapting Neutralizing Antibodies to Viral Variants by Structure‐Guided Affinity Maturation Using Phage Display Technology
por: Peissert, Frederik, et al.
Publicado: (2023)

Mu-opioid receptor selective superagonists produce prolonged respiratory depression
por: Malcolm, Nicholas J., et al.
Publicado: (2023)

Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade
por: Dakhel, Sheila, et al.
Publicado: (2019)

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
por: Knudson, Karin M., et al.
Publicado: (2019)

Efficacy of PEGylated ciliary neurotrophic factor superagonist variant in diet-induced obesity mice
por: Battista, Maria Rosaria, et al.
Publicado: (2022)

Antibody-Mediated Delivery of VEGF-C Promotes Long-Lasting Lymphatic Expansion That Reduces Recurrent Inflammation
por: Cousin, Nikola, et al.
Publicado: (2022)

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
por: Vincent, Marie, et al.
Publicado: (2013)

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
por: White, Ann L., et al.
Publicado: (2015)

75% success rate after open debridement, exchange of tibial insert, and antibiotics in knee prosthetic joint infections: Report on 145 cases from the Swedish Knee Arthroplasty Register
por: Holmberg, Anna, et al.
Publicado: (2015)

New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity
por: Bailey, Cavan P., et al.
Publicado: (2017)

IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
por: Desbois, Mélanie, et al.
Publicado: (2020)

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
por: Knudson, Karin M, et al.
Publicado: (2020)

Design and production of a novel chimeric human growth hormone superagonist fused to human Fc domain
por: Mirbaha, Samira, et al.
Publicado: (2022)

Establishment of mountain birch (Betula pubescens ssp. tortuosa) on a glacial outwash plain: Spatial patterns and decadal processes
por: Óskarsdóttir, Guðrún, et al.
Publicado: (2022)

A universal reporter cell line for bioactivity evaluation of engineered cytokine products
por: Mock, Jacqueline, et al.
Publicado: (2020)

Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer
por: Wei, Pengcheng, et al.
Publicado: (2021)

An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC
por: Fousek, Kristen, et al.
Publicado: (2023)

A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis
por: Murer, Patrizia, et al.
Publicado: (2020)

CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014)

Insights into the Quorum Sensing Regulon of the Acidophilic Acidithiobacillus ferrooxidans Revealed by Transcriptomic in the Presence of an Acyl Homoserine Lactone Superagonist Analog
por: Mamani, Sigde, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j66jag89h56vld72mhjhbmcpo4